Jacobs Levy Equity Management
ACRV icon

Jacobs Levy Equity Management’s Acrivon Therapeutics ACRV Stock Holding History

Jacobs Levy Equity Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-382,234
Closed -$455K – 955
2025
Q2 		$455K Buy
+382,234
New +$525K ﹤0.01% 896
2024
Q1 		– Sell
-46,072
Closed -$227K – 933
2023
Q4 		$227K Buy
+46,072
New +$243K ﹤0.01% 916

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management's ACRV Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 382,234 shares — an estimated $455K sold.

Jacobs Levy Equity Management first reported a position in ACRV in Q4 2023 and held it in 2 quarters. The position peaked at $455K in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 382,234 Acrivon Therapeutics shares in Q3 2025, an estimated $455K.
  • Jacobs Levy Equity Management first reported a position in Acrivon Therapeutics in Q4 2023 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Acrivon Therapeutics position peaked at $455K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.